Craig Sauter1, Juliet N Barker. 1. Adult Allogeneic Bone Marrow Transplantation Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.
Abstract
PURPOSE OF REVIEW: This review summarizes the state of the art of unrelated donor (URD) umbilical cord blood transplantation (UCBT) for the treatment of hematologic malignancies and discusses the current issues associated with the use of this hematopoietic stem cell (HSC) source. RECENT FINDINGS: In contrast to the very high transplant-related mortality associated with the early experience of UCBT, recent series have been associated with comparable survival to that of human leucocyte antigen-matched URD transplantation in children with similarly promising results in adults with the use of double-unit grafts. In addition, utilization of reduced-intensity conditioning regimens has been successful extending access to patients unsuitable for myeloablation. Consequently, the use of umbilical cord blood as a HSC source and the global inventory of units in public banks is rapidly increasing although challenges associated with engraftment, unit quality, and infectious complications remain and will be discussed in this review. SUMMARY: URD umbilical cord blood is an alternative HSC source offering a unique set of advantages and disadvantages as compared with the transplantation of HSC from unrelated volunteers. Improved transplant outcomes are now making UCBT a rival to URD transplantation for the treatment of hematologic malignancies.
PURPOSE OF REVIEW: This review summarizes the state of the art of unrelated donor (URD) umbilical cord blood transplantation (UCBT) for the treatment of hematologic malignancies and discusses the current issues associated with the use of this hematopoietic stem cell (HSC) source. RECENT FINDINGS: In contrast to the very high transplant-related mortality associated with the early experience of UCBT, recent series have been associated with comparable survival to that of human leucocyte antigen-matched URD transplantation in children with similarly promising results in adults with the use of double-unit grafts. In addition, utilization of reduced-intensity conditioning regimens has been successful extending access to patients unsuitable for myeloablation. Consequently, the use of umbilical cord blood as a HSC source and the global inventory of units in public banks is rapidly increasing although challenges associated with engraftment, unit quality, and infectious complications remain and will be discussed in this review. SUMMARY: URD umbilical cord blood is an alternative HSC source offering a unique set of advantages and disadvantages as compared with the transplantation of HSC from unrelated volunteers. Improved transplant outcomes are now making UCBT a rival to URD transplantation for the treatment of hematologic malignancies.
Authors: E Gluckman; V Rocha; A Boyer-Chammard; F Locatelli; W Arcese; R Pasquini; J Ortega; G Souillet; E Ferreira; J P Laporte; M Fernandez; C Chastang Journal: N Engl J Med Date: 1997-08-07 Impact factor: 91.245
Authors: Vanderson Rocha; Myriam Labopin; Guillermo Sanz; William Arcese; Rainer Schwerdtfeger; Alberto Bosi; Niels Jacobsen; Tapani Ruutu; Marcos de Lima; Jürgen Finke; Francesco Frassoni; Eliane Gluckman Journal: N Engl J Med Date: 2004-11-25 Impact factor: 91.245
Authors: Mary J Laughlin; Mary Eapen; Pablo Rubinstein; John E Wagner; Mei-Jei Zhang; Richard E Champlin; Cladd Stevens; Juliet N Barker; Robert P Gale; Hillard M Lazarus; David I Marks; Jon J van Rood; Andromachi Scaradavou; Mary M Horowitz Journal: N Engl J Med Date: 2004-11-25 Impact factor: 91.245
Authors: Juliet N Barker; Daniel J Weisdorf; Todd E DeFor; Bruce R Blazar; Jeffrey S Miller; John E Wagner Journal: Blood Date: 2003-05-08 Impact factor: 22.113
Authors: P Rubinstein; C Carrier; A Scaradavou; J Kurtzberg; J Adamson; A R Migliaccio; R L Berkowitz; M Cabbad; N L Dobrila; P E Taylor; R E Rosenfield; C E Stevens Journal: N Engl J Med Date: 1998-11-26 Impact factor: 91.245
Authors: John E Wagner; Juliet N Barker; Todd E DeFor; K Scott Baker; Bruce R Blazar; Cindy Eide; Anne Goldman; John Kersey; William Krivit; Margaret L MacMillan; Paul J Orchard; Charles Peters; Daniel J Weisdorf; Norma K C Ramsay; Stella M Davies Journal: Blood Date: 2002-09-01 Impact factor: 22.113
Authors: Craig Kollman; Esteban Abella; Robert L Baitty; Patrick G Beatty; Ranajit Chakraborty; Cindy L Christiansen; Robert J Hartzman; Carolyn Katovich Hurley; Edgar Milford; John A Nyman; Thomas J Smith; Galen E Switzer; Randal K Wada; Michelle Setterholm Journal: Transplantation Date: 2004-07-15 Impact factor: 4.939
Authors: David M Harris; Inbal Hazan-Haley; Kevin Coombes; Carlos Bueso-Ramos; Jie Liu; Zhiming Liu; Ping Li; Murali Ravoori; Lynne Abruzzo; Lin Han; Sheela Singh; Michael Sun; Vikas Kundra; Razelle Kurzrock; Zeev Estrov Journal: PLoS One Date: 2011-06-22 Impact factor: 3.240
Authors: Christina Basford; Nicolas Forraz; Saba Habibollah; Kendal Hanger; Colin McGuckin Journal: Int J Stem Cells Date: 2010-05 Impact factor: 2.500
Authors: A S Nelson; L J Ashton; C M Vajdic; R E Le Marsney; B Daniels; I Nivison-Smith; L Wilcox; A J Dodds; T A O'Brien Journal: Leukemia Date: 2014-06-25 Impact factor: 11.528
Authors: Nicolas H Zech; Nikolas Broer; Iris Ribitsch; Mathias H Zech; Karl-Heinz Broer; Kubilay Ertan; Karl-Heinz Preisegger Journal: J Turk Ger Gynecol Assoc Date: 2010-06-01